RNA aptamers depend on both sequence identity and higher-order folding, so synthesis decisions can directly affect binding studies, assay performance, and downstream conjugation. Our custom RNA aptamer synthesis service supports fixed-sequence aptamers, chemically stabilized variants, labeled constructs, truncation panels, and sequence-defined controls for research programs involving proteins, small molecules, cells, nucleic acids, and other experimental targets.
We combine RNA oligonucleotide synthesis with modification planning, purification, analytical verification, and delivery-format control. Projects can incorporate selected 2'-sugar chemistries, modified bases, terminal groups, fluorophores, affinity tags, reactive handles, or linkers when compatible with the aptamer sequence and intended use. For teams working from an established binder, the service is focused on producing chemically defined RNA aptamers that can be folded, compared, immobilized, or conjugated in a reproducible research workflow.
Fig 1. Preparation of RNA aptamer. (Zhou et al., 2012)
Sequence Length & Structure: Aptamers often contain stems, loops, bulges, and compact motifs that can make longer or GC-rich sequences difficult to synthesize and purify. We review length, composition, repeat content, and predicted structural features before selecting the production route.
Nuclease Sensitivity: Unmodified RNA can degrade rapidly in nuclease-containing environments. When compatible with binding function, selected 2'-fluoro, 2'-O-methyl, terminal, or other modifications can be incorporated to support stability-focused research designs.
Modification Tolerance: A modification that improves handling can also disrupt the 3D fold or a target-contacting nucleotide. We prioritize known noncritical positions when that information is available and recommend matched modified/unmodified constructs when tolerance is uncertain.
Purification Resolution: Full-length aptamers must be separated from n−1 and other synthesis products, and the optimal method depends on length, hydrophobic labels, and modification density. Our oligo analysis and purification support can be integrated with the synthesis plan.
Refolding & Formulation: Aptamer binding can depend on salt composition, divalent ions, concentration, temperature history, and refolding protocol. We align delivery format and optional buffer handling with the customer's planned assay rather than treating the sequence alone as the final product.
We support customers who already have an RNA aptamer sequence and need a controlled synthesis route, as well as teams comparing stabilized, labeled, truncated, or conjugation-ready variants. Where broader aptamer development is needed, projects can be coordinated with our custom aptamer synthesis capabilities.
Service configuration is based on sequence length, chemistry, purification target, final format, and the information needed for downstream binding or assay work.
The optimal construct depends on how the aptamer will be folded, detected, immobilized, or challenged in the intended assay. The following options can be combined after sequence-specific feasibility review.
| Construct Option | Primary Purpose | Typical Design Variable | Purification Consideration | Best-Fit Research Use |
| Unmodified RNA aptamer | Preserve the published or selected RNA sequence chemistry | Sequence length, terminal state, folding buffer | HPLC or PAGE depending on length and purity target | Baseline binding, structure studies, mechanism work |
| 2'-Modified aptamer | Increase resistance to ribonuclease degradation in selected contexts | 2'-F or 2'-O-methyl position pattern | Modified chemistry can shift chromatographic behavior | Stability comparisons, cell-associated or matrix-exposed assays |
| Fluorescent aptamer | Enable direct optical readout | Dye identity, attachment site, linker length | Hydrophobic dyes often change retention | Binding assays, localization research, fluorescence detection |
| Biotinylated aptamer | Support capture or surface immobilization | 5'/3' placement, spacer length, single versus multiple biotin | Affinity tag and linker affect separation profile | Pull-down, biosensor, bead-based assays |
| Reactive-handle aptamer | Provide a defined conjugation site | Amino, thiol, azide, alkyne or other compatible handle | Protecting group and post-synthesis handling must be coordinated | Nanoparticle, protein, polymer, or surface conjugation |
| Variant panel | Compare sequence or chemistry changes | Truncations, mutants, label positions, modification patterns | Consistent method preferred across the set | Structure-function mapping and assay optimization |
Providing the right project information at the start reduces avoidable redesign and helps align synthesis with the binding experiment.
| Input | Why It Matters | Examples | Service Decision Affected | Recommended Detail |
| Aptamer sequence | Defines synthesis difficulty and molecular identity | Exact RNA sequence and any noncanonical residues | Route, scale, purification | Provide 5'→3' sequence with clear notation |
| Target & assay format | Helps identify steric and matrix constraints | Protein binding, small-molecule assay, cell binding, biosensor | Label position, linker, delivery format | Describe intended readout and immobilization scheme |
| Known binding motif | Protects functionally important positions from unnecessary modification | Stem-loop, G-quadruplex region, contact residues | Modification placement | Mark critical or previously validated positions when known |
| Stability requirement | Determines whether chemical stabilization should be considered | Serum exposure, nuclease-rich buffer, short biochemical assay | 2' chemistry and terminal protection | State matrix and exposure time |
| Detection requirement | Defines label and spacer needs | Fluorescence, biotin capture, click conjugation | Functional group and attachment site | Specify instrument/readout when relevant |
| Final format | Affects handling after QC | Dry, resuspended, aliquoted, plate format | Concentration and packaging | Provide target concentration, buffer, and aliquot preference |
The workflow is designed around producing a chemically defined aptamer that is compatible with the customer's planned folding and binding experiment.
Collect the exact RNA sequence, target information, assay format, desired quantity, modification map, purity expectation, and final delivery format.
Assess sequence length, composition, modification compatibility, linker needs, and whether a variant panel or segmented strategy is more practical.
Assemble the aptamer with the agreed canonical and modified nucleotides and introduce terminal or internal functional groups where requested.
Use the selected RNase-aware purification method and complete analytical testing appropriate for the construct size and chemistry.
Provide dry or resuspended material and, when requested, coordinate concentration or buffer handling with the customer's downstream folding workflow.
Supply the finalized sequence and modification record, analytical documentation, sample map, and handling information required for the research program.
Aptamer performance can be lost through small changes in chemistry or presentation. Our workflow keeps sequence, modification, purification, and downstream use connected.
Chemically defined RNA aptamers can be configured for a wide range of binding and assay-development workflows without changing the underlying target-recognition concept.
To scope an RNA aptamer project, send the 5'→3' sequence, desired quantity, required modifications or labels, purity expectation, target or assay format, and preferred final delivery condition. We can review whether the requested chemistry is compatible with the aptamer architecture and recommend a practical synthesis, purification, and QC plan. Contact us to discuss a fixed-sequence RNA aptamer, stabilized variant, labeled construct, or comparison panel.
Provide the exact 5'→3' RNA sequence, desired quantity, modifications or labels, purity requirement, target or assay format, and preferred delivery condition. Mark known binding-critical positions when available.
Yes, these chemistries can be considered at selected positions when compatible with the aptamer fold and synthesis route. Modification placement should avoid known target-contacting or structurally essential residues when possible.
The choice depends on aptamer length, sequence, modification density, labels, and required purity. Both HPLC and PAGE can be useful, and the preferred method is selected after reviewing the construct.
Yes. Fluorophores, biotin, reactive handles, and other compatible functional groups can be introduced at defined sites. Spacer length and attachment position should be considered to reduce interference with aptamer folding or binding.
Yes. Variant panels can include parent sequences, truncations, point mutants, stabilized versions, label-position variants, and matched controls with coordinated purification and sample mapping.
Loading ......
